Cover Image
市場調查報告書

肺炎鏈球菌(肺炎球菌)感染疾病:開發平台評估

Streptococcus Pneumoniae (Pneumococcus) Infections - Pipeline Review, H1 2014

出版商 Global Markets Direct 商品編碼 245998
出版日期 內容資訊 英文 114 Pages
訂單完成後即時交付
價格
Back to Top
肺炎鏈球菌(肺炎球菌)感染疾病:開發平台評估 Streptococcus Pneumoniae (Pneumococcus) Infections - Pipeline Review, H1 2014
出版日期: 2014年04月28日 內容資訊: 英文 114 Pages
簡介

肺炎鏈球菌感染感染肺炎鏈球菌的疾病。有輕度也有非常嚴重的病例。其症狀有發燒、惡寒、發汗、疼痛等,致病風險因子有HIV或糖尿病等讓降低免疫系統功能導致健康情況顯著惡化、接受化療等降低免疫系統的治療、還有年鈴等。治療方法有給予抗生劑等。

本報告提供全球肺炎鏈球菌(肺炎球菌)感染疾病治療藥的開發平台相關研究,提供目前開發平台狀況和最新趨勢,藥物簡介,再加上主要企業及開發中的產品檢討等。

目錄

簡介

  • 分析範圍

肺炎鏈球菌(肺炎球菌)感染疾病概要

治療藥的開發

  • 肺炎鏈球菌(肺炎球菌)感染疾病開發中產品:概要
  • 肺炎鏈球菌(肺炎球菌)感染疾病開發中產品:比較分析

肺炎鏈球菌(肺炎球菌)感染疾病:開發中的治療藥:各企業

肺炎鏈球菌(肺炎球菌)感染疾病:開發中的治療藥:大學·研究機關別

肺炎鏈球菌(肺炎球菌)感染疾病:開發中產品概況

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

肺炎鏈球菌(肺炎球菌)感染疾病:開發中的產品:各企業

肺炎鏈球菌(肺炎球菌)感染疾病:開發中的產品:大學·研究機關別

肺炎鏈球菌(肺炎球菌)感染疾病:治療藥的開發企業

  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • 大日本住友製藥
  • Liquidia Technologies, Inc.
  • SK Chemicals Co., Ltd.
  • Panacea Biotec Limited
  • Eurocine Vaccines AB
  • FluGen, Inc.
  • Mucosis B.V.
  • GlycoVaxyn AG
  • Nabriva Therapeutics AG
  • Sinovac Biotech Ltd.
  • Genocea Biosciences, Inc.
  • Serum Institute of India Limited
  • Wellstat Vaccines, LLC
  • Beijing Minhai Biotechnology Co., Ltd
  • Furiex Pharmaceuticals, Inc.
  • ContraFect Corporation
  • Chongqing Zhifei Biological Products Co., Ltd.
  • Sanofi Pasteur SA
  • Valneva SE
  • Abera Bioscience AB

肺炎鏈球菌(肺炎球菌)感染疾病:治療藥的評估

  • 單劑治療藥
  • 標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • Pneumococcal Polysaccharide Vaccine
  • NBP-606
  • V-114
  • GSK-2189242A
  • avarofloxacin hydrochloride
  • S. Pneumoniae Paediatric Next Generation Vaccine
  • Conjugated Pneumococcal Vaccine
  • GSK-2830929A
  • Inactivated Whole Cell Vaccine for Streptococcus Pneumoniae
  • Nucovac
  • Streptococcus Pneumoniae Meningitis Vaccine
  • GEN-004
  • PlyD-1
  • 13-valent Pneumococcal Conjugate Vaccine
  • SIILPCV-10
  • Pneumococcal Conjugate Vaccine
  • Pneumococcal Polysaccharides Vaccine
  • BC-3781
  • Pneumococcus Antibodies
  • PneuGEM
  • Nasal Pneumococcal Vaccine
  • Pneumococcal Vaccine
  • Pneumococcal Vaccine
  • SM-295291
  • SM-369926
  • Vi-PspA Vaccine
  • Pneumococcal Vaccine
  • Multivalent Vaccine For Pneumococcal Disease
  • 15-Valent Pneumococcal Conjugate Vaccine
  • Pneumococcal Vaccine
  • 13-Valent Pneumococcal Conjugate Vaccine
  • Protein-Based Pneumococcal Vaccines
  • Drugs Targeting Gram Positive Bacteria
  • Pneumococcus Pneumolysoid Conjugate Vaccine
  • Pneumococcal Vaccine
  • Vaccine For Streptococcus pneumoniae
  • Pneumococcal Conjugate CRM Vaccine
  • Pneumo Proteic Vaccine
    • 產品概要
    • 作用機制
    • R&D的進展

最新的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發里程碑

  • 關注的新聞·新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC4858IDB

Global Markets Direct's, 'Streptococcus Pneumoniae Infection - Pipeline Review, H1 2014', provides an overview of the Streptococcus Pneumoniae Infection's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Streptococcus Pneumoniae Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Streptococcus Pneumoniae Infection and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Streptococcus Pneumoniae Infection
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Streptococcus Pneumoniae Infection and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Streptococcus Pneumoniae Infection products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Streptococcus Pneumoniae Infection pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Streptococcus Pneumoniae Infection
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Streptococcus Pneumoniae Infection pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Streptococcus Pneumoniae (Pneumococcus) Infections Overview
  • Therapeutics Development
    • Pipeline Products for Streptococcus Pneumoniae (Pneumococcus) Infections - Overview
    • Pipeline Products for Streptococcus Pneumoniae (Pneumococcus) Infections - Comparative Analysis
  • Streptococcus Pneumoniae (Pneumococcus) Infections - Therapeutics under Development by Companies
  • Streptococcus Pneumoniae (Pneumococcus) Infections - Therapeutics under Investigation by Universities/Institutes
  • Streptococcus Pneumoniae (Pneumococcus) Infections - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Streptococcus Pneumoniae (Pneumococcus) Infections - Products under Development by Companies
  • Streptococcus Pneumoniae (Pneumococcus) Infections - Products under Investigation by Universities/Institutes
  • Streptococcus Pneumoniae (Pneumococcus) Infections - Companies Involved in Therapeutics Development
    • GlaxoSmithKline plc
    • Merck & Co., Inc.
    • Dainippon Sumitomo Pharma Co., Ltd.
    • Liquidia Technologies, Inc.
    • SK Chemicals Co., Ltd.
    • Panacea Biotec Limited
    • Eurocine Vaccines AB
    • FluGen, Inc.
    • Mucosis B.V.
    • GlycoVaxyn AG
    • Nabriva Therapeutics AG
    • Sinovac Biotech Ltd.
    • Genocea Biosciences, Inc.
    • Serum Institute of India Limited
    • Wellstat Vaccines, LLC
    • Beijing Minhai Biotechnology Co., Ltd
    • Furiex Pharmaceuticals, Inc.
    • ContraFect Corporation
    • Chongqing Zhifei Biological Products Co., Ltd.
    • Sanofi Pasteur SA
    • Valneva SE
    • Abera Bioscience AB
  • Streptococcus Pneumoniae (Pneumococcus) Infections - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • Pneumococcal Polysaccharide Vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NBP-606 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • V-114 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GSK-2189242A - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • avarofloxacin hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • S. Pneumoniae Paediatric Next Generation Vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Conjugated Pneumococcal Vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GSK-2830929A - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Inactivated Whole Cell Vaccine for Streptococcus Pneumoniae - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Nucovac - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Streptococcus Pneumoniae Meningitis Vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GEN-004 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PlyD-1 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • 13-valent Pneumococcal Conjugate Vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SIILPCV-10 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Pneumococcal Conjugate Vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Pneumococcal Polysaccharides Vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BC-3781 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Pneumococcus Antibodies - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PneuGEM - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Nasal Pneumococcal Vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Pneumococcal Vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Pneumococcal Vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SM-295291 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SM-369926 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vi-PspA Vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Pneumococcal Vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Multivalent Vaccine For Pneumococcal Disease - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • 15-Valent Pneumococcal Conjugate Vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Pneumococcal Vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • 13-Valent Pneumococcal Conjugate Vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Protein-Based Pneumococcal Vaccines - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drugs Targeting Gram Positive Bacteria - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Pneumococcus Pneumolysoid Conjugate Vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Pneumococcal Vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine For Streptococcus pneumoniae - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Pneumococcal Conjugate CRM Vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Pneumo Proteic Vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Streptococcus Pneumoniae (Pneumococcus) Infections - Recent Pipeline Updates
  • Streptococcus Pneumoniae (Pneumococcus) Infections - Dormant Projects
  • Streptococcus Pneumoniae (Pneumococcus) Infections - Discontinued Products
  • Streptococcus Pneumoniae (Pneumococcus) Infections - Product Development Milestones
    • Featured News & Press Releases
      • Mar 11, 2014: Liquidia Technologies Presents New Data on Next-Generation Pneumococcal Vaccines
      • Oct 25, 2013: Synflorix receives positive opinion from the CHMP in Europe for additional pneumonia indication
      • Sep 13, 2013: Nabriva Therapeutics Presented Data on Potency, Safety, Tolerability and Pharmacokinetics of Pleuromutilin Antibiotic BC-3781
      • Feb 25, 2013: Furiex Pharma Receives Qualified Infectious Disease Product And Fast Track Designations From FDA For Avarofloxacin
      • Nov 16, 2012: GlaxoSmithKline Announces Publication Of Positive Results Of Synflorix European Clinical Trial In Lancet In Preventing Invasive Pneumococcal Disease
      • Oct 17, 2012: Durata Therapeutics Announces Preclinical Data Supporting Clinical Development Of Dalbavancin For Treatment Of Pneumonia
      • Oct 09, 2012: GAVI Alliance To Introduce Synflorix Pneumococcal Vaccine In Pakistan
      • Sep 17, 2012: GSK Announces Submission For New Indication For Synflorix In Europe
      • Sep 05, 2012: Rib-X Pharma To Present Data On RX-04 Program At ICAAC 2012
      • Mar 27, 2012: Lorus Therapeutics Announces Positive Results From Small Molecule Antimicrobial Program
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Streptococcus Pneumoniae (Pneumococcus) Infections, H1 2014
  • Number of Products under Development for Streptococcus Pneumoniae (Pneumococcus) Infections - Comparative Analysis, H1 2014
  • Number of Products under Development by Companies, H1 2014
  • Number of Products under Development by Companies, H1 2014 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H1 2014
  • Comparative Analysis by Late Stage Development, H1 2014
  • Comparative Analysis by Clinical Stage Development, H1 2014
  • Comparative Analysis by Early Stage Development, H1 2014
  • Comparative Analysis by Unknown Stage Development, H1 2014
  • Products under Development by Companies, H1 2014
  • Products under Development by Companies, H1 2014 (Contd..1)
  • Products under Investigation by Universities/Institutes, H1 2014
  • Streptococcus Pneumoniae (Pneumococcus) Infections - Pipeline by GlaxoSmithKline plc, H1 2014
  • Streptococcus Pneumoniae (Pneumococcus) Infections - Pipeline by Merck & Co., Inc., H1 2014
  • Streptococcus Pneumoniae (Pneumococcus) Infections - Pipeline by Dainippon Sumitomo Pharma Co., Ltd., H1 2014
  • Streptococcus Pneumoniae (Pneumococcus) Infections - Pipeline by Liquidia Technologies, Inc., H1 2014
  • Streptococcus Pneumoniae (Pneumococcus) Infections - Pipeline by SK Chemicals Co., Ltd., H1 2014
  • Streptococcus Pneumoniae (Pneumococcus) Infections - Pipeline by Panacea Biotec Limited, H1 2014
  • Streptococcus Pneumoniae (Pneumococcus) Infections - Pipeline by Eurocine Vaccines AB, H1 2014
  • Streptococcus Pneumoniae (Pneumococcus) Infections - Pipeline by FluGen, Inc., H1 2014
  • Streptococcus Pneumoniae (Pneumococcus) Infections - Pipeline by Mucosis B.V., H1 2014
  • Streptococcus Pneumoniae (Pneumococcus) Infections - Pipeline by GlycoVaxyn AG, H1 2014
  • Streptococcus Pneumoniae (Pneumococcus) Infections - Pipeline by Nabriva Therapeutics AG, H1 2014
  • Streptococcus Pneumoniae (Pneumococcus) Infections - Pipeline by Sinovac Biotech Ltd., H1 2014
  • Streptococcus Pneumoniae (Pneumococcus) Infections - Pipeline by Genocea Biosciences, Inc., H1 2014
  • Streptococcus Pneumoniae (Pneumococcus) Infections - Pipeline by Serum Institute of India Limited, H1 2014
  • Streptococcus Pneumoniae (Pneumococcus) Infections - Pipeline by Wellstat Vaccines, LLC, H1 2014
  • Streptococcus Pneumoniae (Pneumococcus) Infections - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H1 2014
  • Streptococcus Pneumoniae (Pneumococcus) Infections - Pipeline by Furiex Pharmaceuticals, Inc., H1 2014
  • Streptococcus Pneumoniae (Pneumococcus) Infections - Pipeline by ContraFect Corporation, H1 2014
  • Streptococcus Pneumoniae (Pneumococcus) Infections - Pipeline by Chongqing Zhifei Biological Products Co., Ltd., H1 2014
  • Streptococcus Pneumoniae (Pneumococcus) Infections - Pipeline by Sanofi Pasteur SA, H1 2014
  • Streptococcus Pneumoniae (Pneumococcus) Infections - Pipeline by Valneva SE, H1 2014
  • Streptococcus Pneumoniae (Pneumococcus) Infections - Pipeline by Abera Bioscience AB, H1 2014
  • Assessment by Monotherapy Products, H1 2014
  • Number of Products by Stage and Target, H1 2014
  • Number of Products by Stage and Mechanism of Action, H1 2014
  • Number of Products by Stage and Route of Administration, H1 2014
  • Number of Products by Stage and Molecule Type, H1 2014
  • Streptococcus Pneumoniae (Pneumococcus) Infections Therapeutics - Recent Pipeline Updates, H1 2014
  • Streptococcus Pneumoniae (Pneumococcus) Infections - Dormant Projects, H1 2014
  • Streptococcus Pneumoniae (Pneumococcus) Infections - Discontinued Products, H1 2014

List of Figures

  • Number of Products under Development for Streptococcus Pneumoniae (Pneumococcus) Infections, H1 2014
  • Number of Products under Development for Streptococcus Pneumoniae (Pneumococcus) Infections - Comparative Analysis, H1 2014
  • Number of Products under Development by Companies, H1 2014
  • Number of Products under Investigation by Universities/Institutes, H1 2014
  • Comparative Analysis by Clinical Stage Development, H1 2014
  • Comparative Analysis by Early Stage Products, H1 2014
  • Comparative Analysis by Unknown Stage Development, H1 2014
  • Assessment by Monotherapy Products, H1 2014
  • Number of Products by Top 10 Target, H1 2014
  • Number of Products by Stage and Top 10 Target, H1 2014
  • Number of Products by Top 10 Mechanism of Action, H1 2014
  • Number of Products by Stage and Top 10 Mechanism of Action, H1 2014
  • Number of Products by Top 10 Route of Administration, H1 2014
  • Number of Products by Stage and Top 10 Route of Administration, H1 2014
  • Number of Products by Top 10 Molecule Type, H1 2014
  • Number of Products by Stage and Top 10 Molecule Type, H1 2014
Back to Top